Whilst low-count MBL not often progresses to CLL, superior-count MBL progresses to CLL requiring therapy at a amount of one% to two% per year. Large-rely MBL is distinguished from Rai 0 CLL dependant on whether the B-cell count is over or under 5 × 109/L. Despite the fact that individuals with